Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 49 (6), 1104-1107
- https://doi.org/10.1080/10428190802074619
Abstract
The serum IgM level has been utilised as a marker of tumor progression and to assess response to therapy in patients with Waldenstrom macroglobulinemia (WM). However, there are many limitations to the IgM protein level. The objective of this study was to evaluate the association of known tumor burden markers and prognostic factors with serum free light chain (sFLC) in 98 patients with WM. We demonstrated that sFLC measurement accurately differentiated IgM-MGUS compared with WM reflecting a measurement of tumor burden. In univariate and multivariate analysis, median sFLC at the cut-off at 60 mg/L was higher for WM patients with low hemoglobin and high beta2M, when we applied the WM-IPSS cut-offs, but showed no association with IgM level. This study demonstrates that sFLC is a new marker in WM disease. Further analysis is required to prospectively study the role of sFLC in monitoring response to therapy and as a prognostic marker in WM patients.This publication has 15 references indexed in Scilit:
- Erratum: International uniform response criteria for multiple myelomaLeukemia, 2006
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationBlood, 2006
- Serum Free Light Chains in the Diagnosis and Monitoring of Patients with Plasma Cell DyscrasiasPublished by S. Karger AG ,2006
- Amyloidosis: Diagnosis and ManagementClinical Lymphoma Myeloma and Leukemia, 2005
- Diagnostic Performance of Quantitative κ and λ Free Light Chain Assays in Clinical PracticeClinical Chemistry, 2005
- Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significanceBritish Journal of Haematology, 2004
- Serum free light chains for monitoring multiple myelomaBritish Journal of Haematology, 2004
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)Blood, 2001